UPDATE: Valeant Pharmaceuticals Posts Higher Q2 Profit


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Valeant Pharmaceuticals International (NYSE: VRX) reported a rise in its second-quarter profit. The Laval, Canada-based company reported a quarterly profit of $125.8 million, or $0.37 per share, versus a year-ago profit of $10.8 million, or $0.03 per share. Excluding certain items, its cash earnings surged to $1.91 per share versus $1.34 per share. Its revenue climbed 86% to $2.04 billion. However, analysts were expecting earnings of $1.90 per share on revenue of $2.04 billion. Valeant's same store organic product sales rose 4% in the quarter. Excluding the impact of generics, its same store organic product sales surged 10%. Same store organic sales surged 17% in Asia, while same store sales climbed 13% in emerging markets in Europe. "Valeant once again delivered strong quarterly results and, as expected, organic growth has accelerated from the first quarter," said J. Michael Pearson, chairman and chief executive officer.Valeant shares fell 0.74% to $124.90 in pre-market trading.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: EarningsNewsprofit